Dry Eye Signs and Symptoms Persist During Systemic Neutralization of IL-1β by Canakinumab or IL-17A by Secukinumab

To evaluate whether inhibition of the proinflammatory cytokines IL-1β or IL-17A by canakinumab or secukinumab, respectively, influence the signs and symptoms of dry eye. METHODS: In a randomized, double-masked, placebo-controlled, outpatient clinical trial, 72 patients with moderate to severe dry ey...

Descripción completa

Detalles Bibliográficos
Autores principales: Grosskreutz, Cynthia L., Hockey, Hans-Ulrich, Serra, Denise, Dryja, Thaddeus P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cornea 2015
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4633966/
https://www.ncbi.nlm.nih.gov/pubmed/26418434
http://dx.doi.org/10.1097/ICO.0000000000000627

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4633966/
https://www.ncbi.nlm.nih.gov/pubmed/26418434
http://dx.doi.org/10.1097/ICO.0000000000000627

Ejemplares similares